KR20240125004A - Glp-1 수용체 작용제의 결정 형태 및 이의 제조방법 - Google Patents

Glp-1 수용체 작용제의 결정 형태 및 이의 제조방법 Download PDF

Info

Publication number
KR20240125004A
KR20240125004A KR1020247024148A KR20247024148A KR20240125004A KR 20240125004 A KR20240125004 A KR 20240125004A KR 1020247024148 A KR1020247024148 A KR 1020247024148A KR 20247024148 A KR20247024148 A KR 20247024148A KR 20240125004 A KR20240125004 A KR 20240125004A
Authority
KR
South Korea
Prior art keywords
compound
methyl
crystalline form
characteristic peaks
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247024148A
Other languages
English (en)
Korean (ko)
Inventor
구쥔 쉬
웨이동 루
쥔란 양
전싱 두
치윈 샤오
Original Assignee
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드
샹하이 헨그루이 파마수티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드, 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 filed Critical 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드
Publication of KR20240125004A publication Critical patent/KR20240125004A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247024148A 2021-12-23 2022-12-23 Glp-1 수용체 작용제의 결정 형태 및 이의 제조방법 Pending KR20240125004A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111586541 2021-12-23
CN202111586541.3 2021-12-23
PCT/CN2022/141407 WO2023116879A1 (zh) 2021-12-23 2022-12-23 一种glp-1受体激动剂的结晶形式及其制备方法

Publications (1)

Publication Number Publication Date
KR20240125004A true KR20240125004A (ko) 2024-08-19

Family

ID=86901327

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247024148A Pending KR20240125004A (ko) 2021-12-23 2022-12-23 Glp-1 수용체 작용제의 결정 형태 및 이의 제조방법

Country Status (10)

Country Link
US (1) US20250049778A1 (enExample)
EP (2) EP4455140B1 (enExample)
JP (1) JP2024547112A (enExample)
KR (1) KR20240125004A (enExample)
CN (1) CN118401518A (enExample)
AU (1) AU2022422997A1 (enExample)
CA (1) CA3241677A1 (enExample)
MX (1) MX2024007907A (enExample)
TW (1) TW202328115A (enExample)
WO (1) WO2023116879A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024340407A1 (en) 2023-09-14 2026-04-23 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
JP2023528565A (ja) * 2020-04-01 2023-07-05 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
PL4157832T3 (pl) * 2020-05-27 2024-12-16 Qilu Regor Therapeutics Inc. Sól i postacie krystaliczne agonistów GLP-1R oraz ich zastosowania
CN119930605A (zh) * 2020-09-01 2025-05-06 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
WO2022228490A1 (zh) * 2021-04-30 2022-11-03 上海翰森生物医药科技有限公司 多环类衍生物调节剂、其制备方法和应用

Also Published As

Publication number Publication date
CN118401518A (zh) 2024-07-26
EP4455140B1 (en) 2026-04-01
US20250049778A1 (en) 2025-02-13
EP4455140A1 (en) 2024-10-30
EP4725484A2 (en) 2026-04-15
EP4455140A4 (en) 2025-04-09
CA3241677A1 (en) 2023-06-29
JP2024547112A (ja) 2024-12-26
TW202328115A (zh) 2023-07-16
WO2023116879A1 (zh) 2023-06-29
AU2022422997A1 (en) 2024-07-11
MX2024007907A (es) 2024-07-12

Similar Documents

Publication Publication Date Title
KR20240125003A (ko) Glp-1 수용체 작용제의 약학적으로 허용 가능한 염, 결정 형태 및 이의 제조방법
EP4455140A1 (en) Crystalline form of glp-1 receptor agonist and preparation method therefor
EP4332102A1 (en) Isoquinolone compound and use thereof
CN113993845A (zh) 作为治疗cns障碍例如多发性硬化的gpr17调节剂的n-(苯基)-吲哚-3-磺酰胺衍生物和相关化合物
TW202220962A (zh) 選擇性NaV抑制劑的結晶形式及其製備方法
WO2023124824A1 (zh) 一种glp-1激动剂的盐及其晶型和在医药上的应用
WO2023130878A1 (zh) 一种glp-1激动剂盐及其晶型及在医药上的应用
DE69411143T2 (de) Tryptamin analoge mit 5-ht1d selektivität
JPWO2006095671A1 (ja) キヌクリジン誘導体の新規な塩
US20250361226A1 (en) Pharmaceutically acceptable salt of benzo[c]chroman compound and polymorphic form and use of pharmaceutically acceptable salt
WO2024193455A1 (zh) 一种1,4-二氢-1,6-萘啶酰胺化合物的可药用盐、晶型及其制备方法
TW202408504A (zh) 噻吩[2,3-d]咪唑類化合物的鹽及其晶型和在醫藥上的用途
KR20250020509A (ko) 벤조[c]크로만 화합물의 다형체, 이의 제조 방법 및 이의 용도
EP0765322B1 (en) Indole derivatives as prodrugs of 5-ht1-like receptor agonists
TW202333694A (zh) 稠環衍生物的晶型、其製備方法及其應用
WO2026082108A1 (zh) 一种nlrp3抑制剂用于治疗帕金森病或帕金森综合征的用途
WO2023151660A1 (zh) 一种p2x3受体拮抗剂的结晶形式及其制备方法
WO2025131045A1 (zh) 一种taar1配体激动剂的盐型、晶型及其制备方法和应用
CN120535504A (zh) 一种p38α-MK2抑制剂的晶型及其制备方法和应用
JP2013184934A (ja) オキサジアゾリジンジオン化合物の新規な塩及びその結晶
CN116437917A (zh) Atx抑制剂氘代衍生物及其应用
CN117945945A (zh) 一种gpr139受体激动剂、其制备方法及其应用
CN121159554A (zh) 一种大环钠通道调节剂
WO2025180517A1 (zh) 含sf5类喹啉衍生物及其作为p2x7拮抗剂的用途
HK40062458A (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000